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Editorial
Point of View: Top-down or Bottom-up? A Cardiologist's View Point
on the Proposed Hospital Authority Initiative in Safe Introduction of
New Interventional Service
CHU-PAK LAU1 AND KAM-SANG WOO2
From 1Division of Cardiology, Department of Medicine, Queen Mary Hospital, University of Hong Kong and 2Prince
of Wales Hospital, Chinese University of Hong Kong, Hong Kong

In this issue of the Journal, Chang et al1 describes
a p r opos al mechanism for introduc ing n ew
interventional procedure in the Hospital Authority (HA).
As practising cardiologists, we would like to express a
different view on the proposed mechanism.
It is important first to define the scope of the
current initiative. The initiative addresses the territorywide application of new interventional procedures in
HA hospitals. As such, these procedures should be
relatively well established, with either international or
local evidence. Indeed, a formal ethics committee
approval is unnecessary, because this introduction is
service-oriented and is not a clinical trial. Chang et al1
quoted the application of brachytherapy as an example,
a procedure that has already been shown to be
efficacious and safe in several international randomized
controlled trials.2-3 New innovations which may be novel
treatment, usually carried out as a clinical trial would
need to go through hospital (or university) ethics
committee as stated in the current proposal, and these
trials will not need to go through the proposed HA
initiatives.
The proposed HA initiative is a typical "topdown" mechanism by which an administrative unit in
the HA, in conjunction with a few interested chosen
experts in the field, takes up "the governance and
management approval procedure" for new interventional

Address for reprints: Prof. Chu-Pak Lau
Cardiology Division Chief, Department of Medicine, the University
of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong
Fax: (852) 2855 1143, Email: cplau@hkucc.hku.hk
Opinions expressed are views of the authors and not necessarily
the view of the editorial board or the Hong Kong College of
Cardiology.
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procedures. Such a structure has the advantage of
ensuring a uniform protocol and training requirements
for all centers, and a central monitoring of quality.
The disadvantage of this mechanism is the
"representativeness" of the chosen experts, and the
necessary delay introduced by the administrative
process. For instance, a 6-month delay was encountered
between the application for β-brachytherapy to treat
coronary restenosis and the first case performed. In
addition, because of the rapid evolution of technology,
it may be necessary to repeat the whole process should
a close alternative be introduced. Thus, the mechanism
should build in an alternative is more expedite process,
to allow similar procedures to be approved. In some
hospitals such as the Queen Mary Hospital and Prince
of Wales Hospital, a third mechanism is operative: a
hospital based "Technology and Therapeutic
Subcommittee" is available to "approve" new
interventional procedures at the hospital level.
Traditionally, new interventional cardiology
procedures are introduced in Hong Kong by local
experts in the field, usually in the form of a clinical
trial. For example, the first radiofrequency ablation in
the Asia-Pacific region for paroxysmal supraventricular
tachycardia was introduced in Hong Kong in 1990.4
With training in the technique from the initiating center
in Hong Kong and centers overseas, this procedure is
now generally available in most of the HA hospitals
with catheterization laboratory. This process of
"evolution" from "bottom-up" has the advantage of
being highly flexible with minimal administrative cost
and burden, and with professional freedom that all of
us are used to and would like to continue. Patients'
welfare is safeguarded by the requirement of the ethics
committee, and by the expertise of the initiating
cardiologists. The quality of the service in subsequent
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centers are guaranteed by appropriate training, often
with participation of the cardiologists from the more
experience centers in the initial cases. Quality assurance
and accountability are in the hands of the practising
cardiologists and centres concerned. In the present
funding limitation in the HA in which there are little
additional funds for new procedures/services, these
procedures are introduced with "productivity gain" by
the unit concerned and is highly cost-effective.
Which system should we adopt? We think that
the "old" and "new" are not mutually exclusive, but
complementary. Most of the innovative treatments will
be carried out as clinical trials, under the auspicion of
individual hospital/university ethics committee. When
these innovations have matured to wider clinical
application, or when an established new interventional
procedure is for introduction, there may be a choice
between the "top-down" and "bottom-up" approach. We
believe that the clinicians, acting in the best interests of

2

the patients should have a freedom of choice in their
initiatives. Should additional funding from the HA be
available for introduction of new procedures, a "topdown" initiative would be a logical option.
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Evaluation of Percutaneous Laser Myocardial Revascularization in
Chinese Patients with Refractory Angina Pectoris
CAIYI LU, XUAN WEI, CONGCHUN HUANG, HUILAN LUO, SHUSEN MAO
From Air Force General Hospital, Beijing 100036, PR China
LU ET AL.: Evaluation of Percutaneous Laser Myocardial Revascularization in Chinese Patients with Refractory
Angina Pectoris. The study aims to evaluate the feasibility and effect of percutaneous laser myocardial
revascularization (PMR) in patients with refractory class III-IV angina. Patients were selected by: (1) angina class
≥III; (2) unsuitable to CABG and PTCA; (3) LVEF ≥30%; (4) absence of myocardial infarction in 6 months; (5)
maximum diastolic wall thickness of left ventricle (LV) ≥8 mm in echocardiography. Eclipse Holmium laser generator
and catheter were used. Eighteen patients (17 male and 1 female) with age of 63.3±7.5 years and a history of angina
for 9.6±7.0 years were studied. They were refractory to 5.8±0.7 antianginal drugs. The angina class was IV in 11
patients and III in 9 patients. Maximum diastolic LV wall thickness was 10.2±0.8 mm. LVEF was 41.2±6.2%. Eleven
and 9 patients had triple vessel and double vessel diffuse disease, respectively. A mean of 19.7±6.3 endomyocardial
channels were made. Procedure time was 78.2±12.5 minutes and radiation time 24.3±7.4 minutes. There were no
complications. During the follow-up of 18.7±1.6 months, angina class decreased from 3.8±0.7 to 2.1±0.8 (P<0.05).
Ischemia in SPECT was significantly improved. PMR using Eclipse Holmium laser generator and catheter is safe in
Chinese patients. This results suggest that patients with refractory class III or IV angina could be controlled by
conjunctive use of PMR and regular antiangina drugs. (J HK Coll Cardiol 2000;9:3-8)
Angina pectoris, Holmium laser, myocardial revascularization
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Introduction
The principle of percutaneous laser
endomyocardial revascularization (PMR) is to make
endomyocardial channels in the ischemic left ventricular
walls by translating laser energy via a steerable optic
fiber catheter. From these channels, new capillary
network is reconstructed by angiogenesis development.
The channels are 6 mm in depth and 2 mm in diameter
and are apart from each other by 10 mm. Unlike
angioplasty (PTCA) or coronary bypass (CABG), PMR
is not limited by the characteristic and degree of
coronary vessel lesions, and is suitable to all kinds of
end-stage ischemic heart disease patients who cannot
be revascularized. Therefore, PMR will be a very
important supplement to PTCA/STENT and CABG.1-3
In order to evaluate the feasibility and safety of PMR
in the treatment of Chinese patients with ischemic heart
disease, we analysed the clinical and follow-up date of
18 patients who received PMR procedures in our center
in the recent 2 years.

Material and Methods
Patient Selection
Patient selection has been described in previous
publications.1-5 The 18 cases were selected by the criteria
of: (1) angina pectoris of class III-IV (Canadian Heart
Association Class), 6 (2) refractory to more than 4
antianginal drugs, (3) left ventricular ejection fraction
(LVEF) on echocardiography ≥30%, (4) absence of
acute myocardial infarction in the recent 6 months, (5)
multi coronary vessel diffuse lesions in paroxysmal and
distal parts on coronary angiography, (6) cardiac
ischemia confirmed by treadmill test and/or single
positron emmission computerised tomography
(SPECT), (7) the thickness of target left ventricular wall
in maximum diastolic period on echo ≥8 mm, and (8)
without catheter interventional complications.

(4) synchronization with ECG R wave and adjustable
delay triggered window, (5) Holmium: YAG laser, (6)
usable for both PMR and transmyocardial laser
revascularization. The laser catheter (PMRL-1, Eclipse
Corp., Figure 1) was 110 cm long, comprised of a 9F
XL2 guiding catheter (100 cm) and a 5F L1 laser catheter
(the inner laser fiber, 500 cm). At the tip of the laser
catheter, there is a mirror with a dimension of 1.75 mm
and 4 limiting petals mounted on it.

Procedure
A 9.5F artery sheath was introduced into right
femoral artery by Seldinger technique. Ten thousand
units of heparin was given via the sheath. The LV was
entered with a 6F pigtail catheter, through which a 9F
long sheath was reel rolled into LV. A LV angiogram
was performed with biplane DSA during quiet
breathing. The maximum diastolic LV imaging was
fixed and major LV landmarks were marked on the
video screens. Then the pigtail was withdrawn, and the
laser catheter advanced. The laser generator was
controlled at following parameters: 2 pulses per burst,
2J per pulse, synchronization window lasted 30 ms and
located before the first third of T wave ascending limb.
Delivered energy was calibrated before washing the
catheter system.
The following steps was adapted to make
endomyocardial channels in targeted ischemic LV walls.
Coronary and LV angiograms and echo results were
reviewed to confirm the targeted LV wall. The LV wall
was divided into anterior, lateral, inferior, septal and
blunt apical. The 9F sheath was then directed to the
targeted wall. By the continuous flushing of pressurised
normal saline, the laser catheter and its outer sheath

Equipment
MLAS-1 Holmium: YAG laser generator (Eclipse
Corp., San Francisco, CA, USA) was used. The machine
has the parameters of: (1) wavelength 2100 nm,
continuous adjustable energy from 1 to 6W, (2) pulse
width 200 µ, 2J per pulse and 1-3 pulse delivered per
burst, (3) automatic active energy calibration system,
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Figure 1. PMRL-1 laser catheter system (Eclipse Corp.),
including a XL2 guiding catheter and a L1 fiber catheter.
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were introduced into the LV chamber. The radiopaque
mark at the tip of the laser catheter enabled the operator
to visualize the catheter at the tip of the 9F sheath. The
laser catheter was then advanced until its tip was in
contact with the endomyocardium perpendicularly
(Figure 2); and a laser application was made. The
created channel was marked on the biplane video
screens to ensure the channels were evenly distributed
and to avoid two channels were made at the same point

(Figure 3). The laser catheter was then withdrawn and
the process repeated, until all targeted LV walls were
revascularized. During above procedure, ECG, arterial
pressure and the fluoroscopic heart movement were
monitored.

(A)

(B)

Follow Up
The following parameters were assessed during
follow-up: (1) Angina class, (2) standard 12 lead ECG,

Figure 2. Laser channels were marked on the right anterior oblique 30º(A) and left anterior oblique 45º (B) fluoroscopic screens
of left ventricular angiogram.
(A)

(B)

Figure 3. When perpendicularly pointed to the ventricular endocardium, the tip mark of the laser catheter could be visualized
as a filled rectangle on right anterior oblique 30º (A) and an open circle on left anterior oblique 45º (B), respectively.
5
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(3) treadmill test, (4) echocardiography, (5) SPECT, (6)
cardiac enzymes, (7) LV late potential, and (8) Holter
monitoring.

Statistic Analysis
Categoric data were expressed in percent and
value data in mean ± standard division (M±SD).
Student t test or χ2 test was used to analyse the data
and a P<0.05 was considered to be statistically
significant.

maximum diastolic LV wall thickness was 10.2±
0.8 (9-14) mm with regional motion amplitude of 7.4±
0.7 (5-9) mm. On coronary angiogram, fourteen patients
(78.6%) showed triple vessel disease and 4 patients
(21.4%) had double vessel disease. The LVEF was
43.5±3.7 (42-58)%.

PMR Procedure Data (Table 1)
A mean of 19.7±6.3 (9-30) laser channels were
made on 3±0.9 (2-4) LV walls. A mean of 70.3±11.5
(38-106) laser pulses and 137.9±20.4 (74-210) J were
delivered.

Results
Complications
Patient Data
Eighteen patients (17 male and 1 female) with
age of 65.4±8.2 (51-78) years were studied. Their angina
history was 9.6±7.0 (1-42) years. Their angina class was
3.8±0.7 (class IV in 11 cases and III in 7 cases). They
were refractory to the combination of 4.8±1.7 (3-7) types
of antianginal agents. On SPECT, the ischemic LV walls
were demonstrated in anterior, lateral and inferior walls
(9 patients), anterior, lateral and septal walls (5 patients),
and anterior, lateral and blunt apical walls (4 patients).
All had normal cardiac enzyme, liver and kidney
function and negative LV late potential. On
echocardiography, all patients showed normal cardiac
chamber size without aneurysm and thrombus. The

During laser delivery, all patients did not
experience abnormal sensation. There were no
complications of cardiac perforation, aortic or mitral
valve damage. Ventricular premature contraction was
provoked in 14 (77.8%) patients and nonsustained
ventricular tachycardia was induced in 9 (50.0%) by
intracardiac laser catheter manipulation. Total procedure
time was 78.2±12.5 (48-126) minutes and X-ray
radiation time was 24.3±746 (12-36) minutes.

Early Observation after PMR Procedure
All patients showed normal cardiac enzyme at 6,
12 and 24 hours after PMR procedure. Seven patients
had ST segment resolution in ECG.

Table 1. Channel distribution, pulse and energy data of 18 patients receiving PMR
LV wall
single wall
anterior
lateral
inferior
septal
two walls
A and L
A and I
A and S
three walls
A, L and I
A, L and S
Total

n

laser channel

laser pulse

laser energy

18
14
7
6

11.7±5.1 (7-14)
10.4±2.5 (7-11)
7.8±3.2 (5-9)
8.1±1.8 (6-10)

47.5±9.8 (36-62)
37.0±7.5 (27-42)
31.2±3.5 (23-34)
30.1±4.5 (22-36)

93.6±23.5 (68-118)
69.5±11.9 (26-74)
41.6±7.4 (32-49)
64.1±9.4 (32-76)

18
7
6

18.5±3.5 (7-26)
14.4±4.6 (6-18)
13.8±2.6 (5-21)

66.7±9.1 (36-87)
49.6±9.1 (27-94)
53.2±11.2 (37-86)

119.3±16.3 (70-206)
109.7±13.2 (68-182)
110.2±16.3 (67-176)

7
6
14

17.7±3.4 (7-26)
16.2±3.4 (9-21)
17.6±4.3 (9-26)

68.3±8.3 (34-96)
66.2±7.4 (36-101)
68.3±9.5 (36-104)

138.7±14.6 (72-204)
129.3±16.5 (69-197)
136.4±17.2 (72-208)

Note: A: anterior wall, I: inferior wall, L: lateral wall, LV: left ventricle, S: septal wall

J HK Coll Cardiol, Vol 9
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Follow-up Results (Table 2)
The angina class of all patients was improved
significantly in the follow-up period of 8.7±1.6 (3.511.5) months. The mean reduction in angina class was
1.7±0.4 (1.5-3.5).

Discussion
In this study, we have reported the favorable
experience of PMR in 18 patients with angina who were
refractory to conventional therapy. To ensure safety of
the procedure, the following items should be noted
during PMR operation: (1) Measuring the actual
delivered laser energy to avoid possible abnormal
connection between the catheter fiber and the generator.
The latter can cause the delivered laser energy
abnormally high or low. High energy will lead to cardiac
perforation or damage the cardiac structure, whereas low
energy will decrease the PMR effect. (2) The maximum
number of laser channel for any ischemic LV wall was
limited by the potential complications such as cardiac
perforation, at present the channels for one LV wall is
limited under 12, nearly approaching the density of one
channel per cm2. (3) To prevent cardiac perforation, the
stiff sheath should be manipulated smoothly and without
any resistance in the LV chamber. Pushing forward and
pulling back the sheath as well as the fiber catheter
always under the direction of continuous fluoroscopy,
and biplane X-ray screens were used to locate and
mark the channels. Continuously monitoring
electrocardiogram, arterial pressure and cardiac
movement amplitude were useful. (4) During PMR,
arrhythmias could be provoked by the mechanical

stimulation of catheter manipulation and the delivery
of laser energy. The former could be decreased by the
use of softer or lower profile laser catheters,
individualizing the catheter type and size, adjusting the
catheter contact with the endomyocardium according
to the cardiac movement and ensuring a stable catheter
tip in the LV chamber. Arrhythmia induced during laser
delivery could be prevented simply by synchronizing
the laser energy delivery to the safe period of the cardiac
electric interval.

Conclusion
It is feasible and safe to conduct PMR by Eclipse
Holmium laser generator and catheter in Chinese
patients. PMR allows patient with refractory class III or
IV angina despite conventional treatment to be
controlled.
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Coronary Artery Fistula
WAI-FAT LAM
From Division of Cardiology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong
Kong

Case Report
An 85 years old gentleman presented with
retrosternal chest pain for six months. There was no
heart murmur. Echocardiogram showed mild anterior
hypokinesia; a persantin thallium scan showed partial
reversible defect of the distal LAD territory. The

Figure 1. Right anterior oblique view of the left coronary
system injection. A coronary fistula drained upwards into the
pulmonary artery.

patient underwent a coronary angiogram, which
revealed a patent arteriovenous fistulae originated
from a large first diagonal artery and draining into
the pulmonary artery (Figures 1 and 2). This resulted
in a distal LAD "steal" with subsequent myocardial
ischaemia. The LV ventriculogram revealed a mild
anterior hypokinesia.

Figure 2. Left caudal view showing the orifice of the fistulae
from the diagonal branch.
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Discussion
Coronary artery fistula is uncommon cardiac
lesion but it is the most common congenital coronary
anomaly with haemodynamic consequence. 1 The
incidence of coronary artery fistula in adult population
undergoing coronary angiography study is reported to
0.1-0.2%.3 The natural history of such fistula has not
been studied in large numbers of patients. It is believed
that most of the small lesions are asymptomatic.
Eccleshall et al2 reported a series of 17 fistulae in 14
heart transplant patients followed for a median of six
years. The majority closed spontaneously, none
increased in size and no clinical complications occurred.
Large lesions, however, generally require closure to
prevent complications such as myocardial ischaemia
from a steal phenomenon, endocarditis and potential
aneurysmal dilatation and rupture.
Treatment options include coil embolisation,

10

transcatheter occlusion with covered stents and surgical
ligation. The method of closure depends on the
individual anatomical features of the fistula.
Transcatheter closure with Rashkind double umbrella
or Amplatzer septal occluder has been widely used in
paediatric cases of congenital coronary arteriovenous
fistula and less frequently in adults.1
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ECG Quiz
NGAI-YIN CHAN
From Cardiology Team, Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong
A cardiac consultation about a 76-year-old lady
with chest pain and congestive heart failure was
received. The cardiologist was asked to comment on an
"abnormal ECG" (Figure 1) which was done 10 days
after admission.
What was the rhythm diagnosis ?
1. a) Sinus rhythm
b) Atrial fibrillation
c) Accelerated junctional rhythm
d) Others
The busy cardiologist reviewed the history and
all ECG's. The patient immigrated from China two

months ago. She had history of heart disease and chronic
lung disease. She has been given frusemide and some
unknown medicine. The patient presented with
exertional shortness of breath and atypical chest
discomfort. Clinical examination revealed a 39 kg lady
with tachycardia and congestive heart failure. The
potassium level and renal function was within normal
on admission. The following was the ECG on admission.
(Figure 2)
What was the ECG diagnosis ?
2. a) Atrial fibrillation
b) Atrial flutter with variable block
c) Atrial tachycardia with variable block

Figure 1. "Abnormal ECG" 10 days after admission.
J HK Coll Cardiol, Vol 9
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Figure 2. ECG on admission.

The patient was given aspirin, nitrate and
frusemide. Digoxin loading of 0.25 mg Q8H for four
doses followed by 0.125 mg per day was given orally.
The patient developed nausea, vomiting,
confusion and easy forgetfulness 10 days afterwards.
Clinically she was dehydrated. Serum electrolytes and
blood glucose were normal. Renal function test
was impaired with urea 13.1 mmol/L and creatinine
201 umol/L. CT brain was normal. ECG was done at
that time and was the one mentioned in the cardiac
consultation. (Figure 1)
3. What was the likely unifying cause for the symptoms
and the "abnormal ECG" 10 days after admission?
The digoxin level was 5.6 nmol/L. Digoxin and
frusemide were stopped. The patient was cautiously
rehydrated. The symptoms gradually subsided over
2 weeks' time. The renal function test was then
normalised and the digoxin level dropped to 2.0 nmol/L.
The cardiac rhythm reverted back to that of admission.

12

Answers
1. d) Accelerated junctional rhythm with underlying
atrial fibrillation
2. a) Atrial fibrillation
3. Digoxin toxicity

Discussion
Digoxin toxicity is not an uncommon clinical
problem partly because of its widespread use. Timely
recognition and appropriate management requires
knowledge on the risk factors predisposing to and
clinical manifestations of digoxin toxicity.
Factors predisposing to digoxin toxicity include
hypokalaemia, hypomagnesemia, hypercalcaemia, renal
impairment, advanced age, pulmonary disease and
thyroid disease. In this thin elderly lady with history of
chronic lung disease, a lower maintenace dose of digoxin
should probably be given. The subsequent renal function
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impairment which contributed to digoxin toxicity was
likely to be due to overdiuresis with frusemide.
This patient demonstrated the classical
constellation of gastrointestinal and neurologic
symptoms of digoxin toxicity. Dementia like symptoms
should alert one to look out for chronic digoxin
overdose. Noncardiac manifestations of digoxin toxicity
include anorexia, nausea, vomiting, headache, malaise,
neurologic pain, disorientation, alteration in color
perception, scotoma and halo vision.
Digoxin toxicity produces two major
electrophysiologic effects. The first one is a direct and/
or vagally mediated slowing of conduction and block
in the sinus node and atrioventricular node. This may
cause sinus rate slowing, sinus pauses and
atrioventricular conduction disturbances. The second
one is an enhanced abnormal automaticity and triggered
activity in atrial muscle, atrioventricular junction, HisPurkinje system and ventricular muscle. Specific
arrhythmias of digoxin toxicity include (1) paroxysmal
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atrial tachycardia with variable blood, (2) atrial
fibrillation with complete heart block, (3) second or
third-degree AV block, (4) supraventricular tachycardia
with alternating bundle branch block, (5) complete heart
block with accelerated junctional rhythm or accelerated
idioventricular rhythm, (6) fascicular ventricular
tachycardia. In this patient, the ECG shown in Figure 1
demonstrated a very specific arrhythmia due to digoxin
toxicity. Regularisation of RR interval with underlying
atrial fibrillation shown in leads II, III, V1 and V2 often
represents complete heart block with accelerated
junctional rhythm (with ventricular rhythm >60 bpm).
Apart from arrhythmias, digoxin therapy may
also cause alterations in ST segment and T wave. The
T wave amplitude is lowered and ST segment is
depressed and shortened with occasional appearance of
a prominent u wave. The characteristic ST segment
sagging is also found in this patient. However, it is
always difficult to differentiate it from ST depression
of other causes like myocardial ischaemia.
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Background

The Hospital Authority Scenario

Progress in medicine and breakthroughs from
bio-medical research have resulted in a rapid
proliferation of healthcare technologies including drugs,
equipment and interventional procedures.1 They are
often numerous, costly and holding great promises, with
safety and efficacy yet to be fully established.
Healthcare providers are thus under constant pressure
to decide for timely introduction of appropriate and
worthy technologies for benefit of patients, despite all
the uncertainties involved.
Worldwide experience demonstrates that
regulatory controls over emerging drugs and equipment
are better established than for interventional procedures.
It is not uncommon for the latter to involve intricate
elements of innovation, new consumables, variations
in application, and a high demand on operator skill to
achieve the intended outcome. Such degrees of
complexity often make the situation difficult to manage.
As no interventional procedures are free from hazards,
the decision to introduce a new procedure with its
associated uncertainties is not a simply task. A number
of government agencies and professional bodies have
made attempts to devise assessment tools to manage
this challenge, 2 in an effort to safeguard patient's
wellbeing and uphold professional accountability.

In Hong Kong, the Hospital Authority (HA) has
long established mechanisms to evaluate new drugs and
equipment for safety and efficacy prior to their
introduction into the system. Similar mechanism,
however, is not available for interventional procedures.
Section 22(e) (revised in June 1996) of the Professional
Code of Conduct issued by the Hong Kong Medical
Council stipulates that "The medical practitioner should
consult and obtain approval from the relevant ethical
committee in regard to the use of such surgical
procedures, grafts, implants or medications". When the
HA requested hospitals (or hospital clusters) to set up
their own ethics committees in 1995, it was intended
that they would deal with the introduction of new
interventional procedures as well. Yet the prevailing
practice is that only proposals on clinical trials would
be considered in the hospital ethics committees. Out of
the 12 major acute public hospitals surveyed in April
2000, few had established mechanism to evaluate new
interventional procedures prior to their introduction, and
most did not have explicit or sufficient documentation
requirements for such reviews. Situation does not seem
to be more assuring in the private sector (personal
enquiry). Anecdotal reports that new procedure of
unproven efficacy had been performed on patients
highlight the need for an explicit mechanism in HA and
perhaps Hong Kong as a whole.
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Evolution of HAMSINP
In January 2000, the Coordinating Committee in
Surgery reported to the Medical Services Development
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Committee (MSDC) that a mechanism would be set up
to vet new surgical procedures prior to their introduction
into HA. Members of MSDC received the proposal with
great enthusiasm. Thus, the Chairman, Dr the
Honourable CH Leong requested an explicit mechanism
to be established and implemented on the 1 January 2000
to cover all clinical specialties.
The 'HA mechanism for the safe introduction of
new procedures' (HAMSINP) was designed to close a
loophole in the existing system and to provide guidelines
and tools for HA staff to appraise new interventional
procedures and to document such activities. It was
planned with the following principles in mind:
1. It is considered unethical to plan an introduction of
new interventional procedure into the HA service
without going through proper peer review.
2. The mechanism must not stifle clinical innovation
but should, instead, facilitate timely assessment of
new procedures aiming at their safe and effective
introduction.
3. The mechanism would enhance accountability to
public, protecting interests of patients as well as the
clinicians and hospitals, through compliance with
an impartial process that is explicit, transparent and
benchmarked against international best practice.
4. The mechanism provides due recognition of staff
initiative, originality and fosters spirit of shared
learning.
Key results shall include:
1. Establishing Standard Operating Procedures (SOP)
for collecting, collating and analyzing evidence
concerning the safety and efficacy of submitted new
procedure, and making recommendations regarding
appropriate method of introduction into the HA
services.
2. Harmonizing vetting standards by providing a set
of unified procedures and appraisal tools.
3. Establishing documentation requirements that permit
retrospective evaluation of the conduct of the review
and the quality of the decision reached.
4. Enhancing cooperation and implementation planning
to minimise patient risks in going through many
learning curves of individual operators and centres.
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5. Setting up a central register to facilitate information
dissemination.
6. Developing a culture of accountability through
evidence-based decision making, independent peer
review and procedural transparency.

The Approach
We scanned websites for similar set ups in the
developed countries and conducted meetings to solicit
inputs from leading surgical specialists from both
Universities and HA hospitals. It was generally agreed
that the Australian Safety and Efficacy Register of New
Intervention Procedure - Surgical (ASERNIP-S)3 was
a model suitable for our adaptation. In April 2000, we
were fortunate to be offered an opportunity by Pamela
Youde Nethersole Eastern Hospital to test this model
on an application of intracoronary brachytherapy.4 We
subsequently developed a set of SOP and appraisal tools
using the evidence-based medicine approach.5,6 These
documents, grouped as HAMSINP during consultation,
constituted a common platform of discussion whereby
all interested staff could contribute their ideas. In
developing the SOP, we took care to align the
governance and management approval procedure with
the existing accountability structure in the HA hierarchy
(Figure 1).7
HAMSINP is application driven and its success
is thus contingent upon professional integrity and a
culture of accountability. Our professional obligation
dictates that all clinicians must assess safety and efficacy
issues before making changes or incorporates new
innovations in interventional procedure to their practice.
HAMSINP simply states these requirements and
emphasizes the need for systematic searching and
appraisal of evidence. The single unitary public hospital
system in Hong Kong which, covers over 90% of the
market, provides a unique opportunity to enable a
healthcare technology assessment tool with high
likelihood of success.
Noting that mutual understanding and trust are
prerequisite for the successful implementation of
HAMSINP. We would be holding more than 30 briefing
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INTRODUCTION OF NEW INTERVENTIONS

Submit New Procedure
Application with Review
Protocol to COS/HCE

Check
with
DD(MSD)
if the procedure is
new to HA?

No

Advice
HCE

Yes

Review by HAMSINP
CEU

COC

or

Is
evidence
straightforward
for approval or
rejection?

No

Abbreviations:
CE: Chief Executive
CEU: Clinical Effectiveness Unit
COC: Coordinating Committee
COS: Chief of Service
DD(MSD): Deputy Director (Medical Services Development)
HA: Hospital Authority
HCE: Hospital Chief Executive
HGC: Hospital Governing Committee
MSDC: Medical Services Development Committee

Yes

Commission Review Group

Ratify by CE / designate

Inform applicant and HCE of recommendation.
File in the HAMSINP Register.

Figure 1. An overview of the HAMSINP mechanism.
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sessions and open forum for major specialty
Coordinating Committees, Hospital Governing
Committees and frontline practitioners to solicit their
comments.

the existing hospital ethics committee infrastructure
needs further development to match our community's
expectation.

Conclusion
What Have Been Confirmed
in the Consultation Process?
During consultation, both heat and light were
generated for HAMSINP. Concepts such as professional
autonomy, public accountability and practicability were
rigorously examined and debated upon among
enthusiastic colleagues. No one was left in doubt of the
principles and concepts of the proposed mechanism but
many had shown concerns over how much could be
achieved at the end. Many had pointed out difficulties
such as resources constraint and a prevailing culture of
competition among some hospitals that might obstruct
shared learning.
HAMSINP is application driven. It is not a
policing tool. The actual appraisal will be performed
by peers utilizing methods established in evidence-based
medical practice. This heavy involvement by clinicians
should strengthen the basis and further promotes
professional autonomy rather than limiting it as feared
by some colleagues. HAMSINP would not infringe upon
a clinician's sacrosanct privilege and duty in taking care
of his/her patients. In unforeseen circumstances where
a new procedure may be life saving, the accepted
practice to "act in good faith" would prevail over a
prescribed mechanism for normal use. Despite all
considerations and efforts to design a "perfect"
mechanism, the HAMSINP would need to evolve over
the years to fully achieve its intended objectives.
Innovations and hypothesis that needs to be
tested by clinical trials should be referred to the ethics
committee for consideration. The latter's scope is
much wider, covering issues such as bio-medical
ethics, scientific values and quality standards in the
designing, conducting, recording and reporting of
clinical trials.8 It is the authors considered view that
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The HAMSINP helps to close a "loop hole" in
the existing system where some new procedures will
escape proper assessment by bypassing the ethics
committee. The limited experience we have gained
suggested reasonable confidence on its feasibility and
practicality. By making the best evidence and sound
recommendations clearly documented and readily
available, it will certainly facilitate better decisionmaking at all levels of healthcare in the Authority.
Readers interested in obtaining a copy of the
SOP, and or providing any comments, should contact
Dr SP Lim at splim@ha.org.hk.
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